Share Name Share Symbol Market Type Share ISIN Share Description
AstraZeneca LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +26.50p +0.54% 4,938.50p 4,938.00p 4,939.00p 4,957.00p 4,908.00p 4,928.50p 424,022 10:36:38
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 18,627.4 2,876.5 224.3 24.2 62,503.66

AstraZeneca (AZN) Latest News (1)

More AstraZeneca News
AstraZeneca Takeover Rumours

AstraZeneca (AZN) Share Charts

1 Year AstraZeneca Chart

1 Year AstraZeneca Chart

1 Month AstraZeneca Chart

1 Month AstraZeneca Chart

Intraday AstraZeneca Chart

Intraday AstraZeneca Chart

AstraZeneca (AZN) Discussions and Chat

AstraZeneca Forums and Chat

Date Time Title Posts
22/9/201714:28AstraZeneca2,020
03/4/201720:08Potential Reaction on AstraZeneca (AZN)-
29/8/201618:09Analysts' View on AstraZeneca (AZN)-
29/8/201600:47*** AstraZeneca *** 357
14/3/201613:28AstraZeneca : 38.1% Potential Upside Indicated by Deutsche Bank4

Add a New Thread

AstraZeneca (AZN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
09:36:384,938.501507,407.75AT
09:36:374,938.50462,271.71AT
09:36:374,938.501658,148.53AT
09:36:374,938.501356,666.98AT
09:36:374,938.50884,345.88AT
View all AstraZeneca trades in real-time

AstraZeneca (AZN) Top Chat Posts

DateSubject
25/9/2017
09:20
AstraZeneca Daily Update: AstraZeneca is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AZN. The last closing price for AstraZeneca was 4,912p.
AstraZeneca has a 4 week average price of 4,432.50p and a 12 week average price of 4,260p.
The 1 year high share price is 5,520p while the 1 year low share price is currently 3,996p.
There are currently 1,265,640,640 shares in issue and the average daily traded volume is 2,569,114 shares. The market capitalisation of AstraZeneca is £62,712,493,712.
30/7/2017
19:12
nw99: Finally, Sabah Meddings, writing for Sunday Times' 'Inside The City' column, looked at AstraZeneca, with a share price that plunged last week after it revealed its key 'Mystic' cancer drug trial had produced disappointing results.The drugmaker had tried its best to deflect the bad news by highlighting ann $8.5bn partnership with Merck over its Lynparza cancer treatment, as well as positive phase III results for another of its cancer candidates Tagrisso.But investors were having none of it, wiping £10bn off the value of AstraZeneca in a single day.Meddings suggested the City may have overreacted, however, saying the crash could have been exacerbated by uncertainty over the future of the company's chief Pascal Soriot, and pointing out Neil Woodford's decision to continue to back Astra over rival GlaxoSmithKline.Woodford had noted that Astra remained "very attractive" - comments backed up by Citi's 'buy' rating on the stock.Meddings said Astra's shares looked cheap compared to GSK at 22 times earnings - about half of Glaxo's valuation - but added that Astra's value wasn't wildly different to the rest of the sector globally.She said that - Mystic aside - the results were "OK", as revenue fell 11% to $10.5bn in the first half, in line with expectations, and profits still leaping 22% to $1.8bn even after accounting for weak sterling.Meddings said it would take time for other projects to emerge from the lab in an investable state, although ongoing speculation of a potential bid from Novartis would likely "keep a floor" on Astra's price."Therefore, Astra looks like a reasonable each-way bet - and one that pays a dividend."
28/7/2017
15:10
minerve: My comment from yesterday: "Minerve 27 Jul '17 - 10:46 - 1954 of 1988 0 0 Edit This is oversold IMO. Just looking at TPs, consensus affects on earnings and past share price history I would say a stabilising share price should sit around 4675." Pretty good, huh?
27/7/2017
10:46
minerve: This is oversold IMO. Just looking at TPs, consensus affects on earnings and past share price history I would say a stabilising share price should sit around 4675.
27/7/2017
10:10
steeplejack: Well,I guess the analysts have run their adjustments of new discounted cash flow calculations on Mystic accounting for this giant setback/failure.The share price has retreated back to where it was end Feb.A correction of 15% on the day,is fairly unforgiving but understandable.I'm not selling but I'm unprepared to buy into a dead cat bounce or the wishful thinking of a bid.For now,there's consolation in the dividend.
27/1/2017
09:02
steeplejack: Goldmans issued a sell note on the 24 Jan with a £39 share price target.Thats probably still washing through.
20/1/2017
17:26
philanderer: "Is Neil Woodford a fool to continue pumping money into Capita plc and AstraZeneca plc? 'Patience' AstraZeneca is Woodford's largest holding and an example of just how long he's prepared to be patient with a company he views as intrinsically undervalued. Earnings at the pharma group have suffered as a result of expiring patents on some of its top sellers and no improvement is expected to the bottom line until 2018. However, the company has maintained its dividend through this difficult period and offers a 5% yield at a current share price of around 4,400p. The dividend is forecast to start rising with the resumption of earnings growth in 2018 as a result of Astra's reinvigorated drugs pipeline. HTTP://money.aol.co.uk/2017/01/20/is-neil-woodford-a-fool-to-continue-pumping-money-into-capita-pl/
06/12/2016
09:19
bili1946: I have looked through the last months target share price from 12 brokers.....range from £46 to £60? Today,s latest £55?
12/5/2016
11:34
philanderer: ‘Hold’ AstraZeneca for ‘cutting-edge’ drugs pipeline Shore Capital has resumed coverage of pharmaceutical giant AstraZeneca (AZN) as the company undergoes a period of transition. Shore Capital analyst Tara Raveendran initiated coverage of the UK drugs company with a ‘hold’ but did not set a share price target. ‘AstraZeneca is undergoing a period of transition,’ she said. ‘Its mature franchises are slowing in the face of competition and genericisation, however, it boasts a full but emerging pipeline of unique assets in existing and new therapeutic areas that are not yet contributing to the top-line. ‘While we are more positive over the medium to longer term, encouraged by management’s commitment to cutting-edge science and its exciting pipeline, lacklustre earnings and limited pipeline visibility are likely to be near-term overhangs for the stock,’ she added. This week the company borrowed €2.2 billion in a private loan note placing on which it will pay a fixed coupons of 0.25%, 0.75% and 1.25%. Yesterday the shares added 8.5p or 0.2% to £39.36. HTTP://citywire.co.uk/money/the-expert-view-william-hill-aa-and-astrazeneca/a907553?re=40070&ea=290170&utm_source=BulkEmail_Money_Daily&utm_medium=BulkEmail_Money_Daily&utm_campaign=BulkEmail_Money_Daily#i=4
16/2/2016
06:15
indianspan: http://www.4-traders.com/ASTRAZENECA-PLC-4000930/news/AstraZeneca-38-1-Potential-Upside-Indicated-by-Deutsche-Bank-21856171/ AstraZeneca plc with EPIC/TICKER had its stock rating noted as Retains with the recommendation being set at BUY this morning by analysts at Deutsche Bank. AstraZeneca plc are listed in the Health Care sector within UK Main Market. Deutsche Bank have set a target price of 5700 GBX on its stock. This now indicates the analyst believes there is a possible upside of 38.1% from the opening price of 4128.5 GBX. Over the last 30 and 90 trading days the company share price has decreased 82 points and decreased 171.5 points respectively. AstraZeneca plc has a 50 day moving average of 4,407.83 GBX and a 200 day moving average of 4,329.91 GBX. The 52 week high share price is 4931.68 GBX while the 52 week low is 3746 GBX. There are currently 1,261,546,027 shares in issue with the average daily volume traded being 3,095,152. Market capitalisation for is 51,994,619,5ase (CKD), diabetes mellitus (DM) and chronic heart failure (CHF). All rights reserved (c) 2016 The Jerusalem Post Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers Envoyer par mail 03 GBP.
02/5/2014
08:43
harvester: Share price below indicative offer since not all cash offer and risk of pfizer share price weakening as well as risk of the deal failing . AZN share price closed last night at 4851 up 151 based on suspicious after hours trades . At normal market close the share price was 4676.5 . Big money at stake. Hence bound to be some insider trading going on .
AstraZeneca share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V: D:20170925 09:51:39